Big Moving Stock chart patterns and volume.
OSIR Osiris Therapeutics, Inc.
Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing of therapeutic products to treat medical conditions in the inflammatory, cardiovascular, orthopedic, and wound healing markets. It operates in two segments, Biosurgery and Therapeutics. The Biosurgery segment develops, manufactures, and distributes biologic products for orthopedic, wound healing, and surgical procedures by harnessing the ability of cells and novel constructs for the body's natural healing. It offers Grafix for application to acute and chronic wounds, including diabetic foot ulcers and burns; and Ovation for use in surgical applications. This segment markets and distributes its products directly to hospitals and clinics, as well as through a network of distributors. The Therapeutics segment develops and markets products to treat medical conditions in the inflammatory and cardiovascular disease areas. It offers Prochymal for the treatment of refractory acute graft versus host disease in children. This segment also develops biologic stem cell drug candidates, such as Prochymal that is in clinical trials for various indications, including acute graft versus host disease in pediatric and adult patients, Crohn's disease, and acute myocardial infarction; and Chondrogen for osteoarthritis and cartilage protection. The company has a collaborative agreement with Juvenile Diabetes Research Foundation for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook17 Mar 2015, 10:45 amPharma Stock Outlook: Let's Make a Deal - Industry Outlook
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews17 Mar 2015, 10:45 amPharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
Osiris Therapeutics (OSIR) in Focus: Stock Jumps 8.6% - Tale of the Tape9 Mar 2015, 7:18 amOsiris Therapeutics, Inc. (OSIR) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
Osiris Therapeutics' Q4 Earnings Down Y/Y, Revenues Soar - Analyst Blog6 Mar 2015, 9:20 amOsiris Therapeutics (OSIR) reported fourth-quarter 2014 earnings of 3 cents per share, down from the year-ago earnings of 5 cents.
Osiris posts 4Q profit5 Mar 2015, 7:09 amThe Columbia, Maryland-based company said it had profit of 2 cents per share. Earnings, adjusted to account for discontinued operations, were 3 cents per share. The developer of treatments using adult ...
Osiris Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results: For the Full Year, Revenue Increased ...5 Mar 2015, 6:00 amOsiris Therapeutics, Inc. , the leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orth